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Abstract. A primary peptide of the renin angiotensin system (RAS), Angiotensin (Ang) II, is a 19 
vasoconstrictor and promotor of atherosclerosis. To counter this, the RAS also consists of peptides and 20 
receptors which increase nitric oxide release from the endothelium and decrease nicotinamide adenine 21 
dinucleotide phosphate oxidase-related superoxide production. Two peptides, Ang (1-7) and alamandine 22 
are vasodilators, by activating the nitric oxide pathway via different receptors in the endothelium. Thus, 23 
herein we focus on the similarities and differences between alamandine and Ang (1-7) and the 24 
counterbalancing hypothesis on Ang II during endothelial dysfunction and atherosclerosis. 25 
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1.1 Introduction 45 
Cardiovascular disease (CVD) accounts for 1 in 3 deaths worldwide [1] with increasing prevalence in the 46 
Western world. Despite the therapeutic advances for treating CVD [2], novel interventions are necessary 47 
to further reduce this burden. The renin angiotensin system (RAS) is a hormone system that regulates 48 
blood pressure, electrolyte balance and plays a crucial role in atherogenesis and thus CVD.  49 
Atherosclerosis is a progressive process of arterial wall thickening and is characterised by the deposition 50 
of lipoproteins, cholesterol and white blood cells on the innermost layer of blood vessels [3]. 51 
Atherogenesis is complex, however 3 distinct stages have been identified. (1) Endothelial dysfunction, 52 
which occurs throughout all stages of atherosclerosis; (2) plaque formation, and, (3) thrombosis [4-6]. 53 
These stages occur at the luminal surface of blood vessels and are time-dependent [7]. Endothelial 54 
dysfunction is a pathophysiological shift towards a vasoconstrictive and pro-inflammatory state. This is 55 
believed to occur mainly due to a reduction in the bio-availability of nitric oxide, possible due to an 56 
altered activity of endothelial nitric oxide synthase (eNOS) [8] or an over-activation of the protein kinase 57 
C (PKC) signalling pathway [9] coupled with an overproduction of superoxide [10, 11]. Over-activation 58 
of RAS has been linked to endothelial dysfunction and may be involved in altering protein kinases, eNOS 59 
activity and superoxide production, ultimately regulating atherogenesis. Thus, drugs regulating RAS are a 60 
promising therapeutic modality against CVD. 61 
The RAS includes a number of peptides and enzymes, including Ang II, angiotensin converting enzyme 1 62 
(ACE1), ACE2, angiotensin A (Ang A, where the A is abbreviated for alanine), angiotensin (1-7) (Ang 63 
(1-7)), Mas receptor, Mas-related G coupled protein receptor member D (MrgD) and alamandine [12-14]. 64 
The RAS is present in a number of tissues including, blood vessels, myocardium, kidney and brain [15-65 
18]. The pathway begins with angiotensinogen, which is formed in the liver and released into the 66 
circulation.  It is proteolyzed by renin resulting in a the decapeptide, Ang I. Ang I binds to the endothelial 67 
cell layer of blood vessels, and ACE1 cleaves the C-terminal dipeptide (L-histidyl-L-leucine) of Ang I to 68 
form Ang II [19-21] (Figure 1).  69 
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Ang II and Ang A have vasoconstrictive properties, which act through the angiotensin II type I receptor 70 
(AT1) [14, 22]. AT1 is a 41 kDa transmembrane receptor highly expressed in the cardiovascular system 71 
and regulates aldosterone secretion and controls blood pressure [23]. Binding of Ang II to AT1 receptor 72 
stimulates an array of pathophysiological actions including, vasoconstriction, which elevates blood 73 
pressure, endothelial dysfunction (inhibition of NO production) and increases nicotinamide adenine 74 
dinucleotide phosphate (NADPH) oxidase activation for superoxide production; leading to the 75 
development of cardiac fibrosis, inflammation associated with atherosclerosis and atherosclerotic plaques 76 
[24-28]. In addition, Ang II may act through the angiotensin II type II receptor (AT2) resulting in 77 
vasodilatory effects. AT2 is highly expressed in the developing fetus, however, its expression is low in the 78 
cardiovascular system but is increased in inflammation, hypertension and atherosclerosis and is 79 
vasoactive in human radial arteries [29]. Likewise, alamandine, is hydrolyzed by ACE2 from Ang A or 80 
decarboxylated from Ang (1-7), also exerts vasodilatory and anti-hypertensive actions, through the MrgD 81 
receptor [12, 30]. Ang (1-7) is also a vasodilator which acts via the Mas receptor, which is related to the 82 
MrgD receptor. Therefore, the localization of both the MrgD and the Mas receptor on endothelial cells 83 
suggests that both alamandine and Ang (1-7) may play important roles in blood vessel physiology [22, 84 
31]. In addition, Ang (1-7) exerts an anti-angiogenic role by decreasing proangiogenic hormones such as 85 
vascular endothelial growth factor-A [12, 32]. However, there are no reports to demonstrate the effect of 86 
alamandine on angiogenesis. Furthermore, ingestion of alamandine/cyclodextrin decreases the 87 
accumulation of collagen I, III, and fibronectin in isoproterenol-treated rats, contributing to a decrease in 88 
cardiac fibrosis [12].  Interestingly, research performed in our laboratory showed a marked reduction in 89 
rat aortic wall elastic fibers after an atherogenic diet for 15 weeks [33], and thus it would be interesting to 90 
determine if alamandine can reduce this pathological effect.  Therefore, Ang (1-7) and potentially 91 
alamandine acting via their specific receptors, may be able to decrease endothelial cell proliferation and 92 
migration, resulting in a decrease in endothelial cell permeability, and thus an attenuation of 93 
atherogenesis. 94 
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Both the Mas and the MrgD receptors are proto-oncogenes. The Mas proto-oncogene was first identified 95 
in 1986 where it was noted to facilitate tumorigenesis, and similarly for the overexpression of the MrgD 96 
receptor in murine fibroblast cell lines [34, 35]. Thus, if alamandine and Ang (1-7) are to be used as a 97 
treatment for CVD, these peptides could affect oncogenesis. Thus, it is important to determine a possible 98 
carcinogenic/oncogenic effect in animal models using alamandine and Ang (1-7) in a combined 99 
CVD/cancer model.        100 
Ang (1-7) counterbalances the effects of Ang II exerted on human cerebral smooth muscle cells [25]. 101 
These effects reduce Ang II-induced apoptosis and proliferation [25]. Indeed, in vitro studies show that 102 
administration of Ang (1-7) to rat aorta prevents Ang II-stimulated reactive oxygen species (ROS) 103 
production [24] and increases NO release resulting in increased vasodilation [36], and reduces endothelial 104 
oxidative stress. We are unaware of studies that demonstrate alamandine counterbalancing Ang II effects 105 
on vascular smooth muscle cells and on endothelial cells. It is possible that alamandine may mimic the 106 
effects of Ang (1-7), due to the close homology of their amino-acid sequence (Figure 1 and 2). Indeed, 107 
alamandine stimulates NO release potentially by eNOS in endothelial cells to induce vasodilation through 108 
the MrgD receptor [12]. Thus, combined Ang (1-7)/alamandine would be viable pathways to reduce Ang 109 
II-associated endothelial dysfunction (i.e. low NO release from endothelium), Ang II-associated vascular 110 
proliferation, and Ang II-associated inflammation during atherosclerosis.    111 
1.2 Biosynthetic pathway for of Ang (1-7) and Alamandine 112 
The RAS exists in the circulatory and tissue system and circulatory-Ang II is synthesized when ACE 113 
cleaves the C terminal dipeptide of the renin-catalyzed-angiotensin I [37]. An intracellular form of renin, 114 
as well as angiotensin I and both forms of ACE expressed in tissues have been associated with increased 115 
intracellular Ang II production [38]. Therefore, the formation Ang (1-7) and alamandine, can also be 116 
biosynthesized at a circulatory and tissue level. As revised by Zhang et al (2015), ACE2 catalyzes 117 
angiotensin (1-9) from angiotensin I, so that angiotensin (1-9) can be cleaved by ACE into Ang (1-7).  118 
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Moreover, Ang II can be directly converted into Ang (1-7) via ACE2 [39]. Also, carboxylase can convert 119 
Ang (1-7) to alamandine. Similarly to Ang (1-7), alamandine can be synthesized at the circulatory and 120 
tissue system (Figure 1). 121 
 122 
Figure 1: The pathway for both alamandine and Ang (1-7).  Whether Ang A is formed from Ang I remains unknown.  However, Ang A has been 123 
demonstrated through chromatographic purification and structural analysis that it is mostly likely generated enzymatically from Ang II via 124 
decarboxylase [14]. Ang I can be cleaved into Ang (1-7) by prolyl endopeptidase (PEP) [40], matrix metalloproteinase-8 (MMP8) [41] and prolyl 125 
carboxypeptidase (PCP) [42].  126 
 127 
1.3 Factors involved in vascular dysfunction, leading to atherosclerosis 128 
The widely studied vasodilator produced by the endothelial layer of blood vessels is the free radical gas, 129 
NO [43]. NO contributes to normal vascular homeostasis and reduced NO bioavailability results in 130 
endothelial dysfunction [44, 45]. CVD risk factors, such as type 2 diabetes, hypertension, and 131 
hypercholesteremia exacerbate the reduction of  NO bioavailability thus promoting atherosclerosis. Since 132 
atherosclerosis is the primary cause of CVD, the pharmacological drive to reverse endothelial 133 
dysfunction, by improving NO release, should improve vascular health and reduce the burden of CVD. In 134 
addition, ROS released by cells, including endothelial cells, is a byproduct of oxygen in normal 135 
homeostasis. During stress however, ROS is produced in excessive levels leading to cell damage (cellular 136 
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oxidative stress). In fact, overproduction of Ang II leads to dramatic increase in ROS production by 137 
endothelial cells, through the NADPH oxidase enzyme inducing cellular oxidative stress, leading to 138 
endothelial dysfunction, endothelial apoptosis and promotion of thrombosis formation [46-48]. Hence, 139 
cellular oxidative stress and reduction in NO, contribute to endothelial dysfunction [49-51]. Furthermore, 140 
RAS peptides and enzymes are increased in cardiovascular disease in tissues, such as, blood vessels [22], 141 
kidney [52], cardiomyocytes [53], skeletal muscle cells [54] and the colon [55], hence treatment 142 
modalities are targeted to reduce the systemic over-activation of the RAS. 143 
  144 
1.4 Trophic effects of RAS peptides on endothelial cell function and vascular tone regulation  145 
Vascular endothelial cells release trophic factors such as NO, neutral endopeptidase, prostaglandin I2 and 146 
endothelin-1 that regulate vascular tone. An imbalance of these vasoactive factors may lead to an 147 
imbalance of vascular tone and induce proliferation of VSMCs, leading to hypertension and 148 
atherosclerotic plaque accumulation. Although physiological levels of Ang II, upon stimulation of the 149 
AT1 and AT2 receptors on endothelial cells signal vascular tone and proliferation, pathophysiological 150 
levels of Ang II disrupts this homeostasis and induces excess VSMC proliferation in rodents, rabbits and 151 
humans [56-58].  In mice and rat, two weeks of Ang II infusion via mini-osmotic pumps induces 152 
hypertension, cardiac and VSMC hypertrophy, and endothelial dysfunction [59]. Indeed, in humans, an 153 
imbalance between Ang (1-7)/Ang II ratio has been shown in systemic sclerosis-induced endothelial 154 
dysfunction [60]. Furthermore, Ang(1-7) infusion inhibits  VSMC proliferation in balloon-injured carotid 155 
arteries of rats [61]. Although further evidence is required to fully elucidate the mechanistic pathway 156 
elicited by Ang (1-7), most in vitro studies conducted on human or rodent  cultured aortic endothelial 157 
cells show that after Ang (1-7) and its associated receptor signalling on the endothelial cell surface, an 158 
array of enzymes are phosphorylated, such as phosphoinositide 3-kinase/AKT, protein kinase A, 159 
phospholipase A2  phosphorylation leading to increased production of eNOS-induced NO and cyclic 160 
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AMP production [36, 62]. Ang (1-7) has also been shown to cause a reduction of mitogen-activated 161 
protein kinase (MAPK) phosphorylation concomitant with a reduction of extracellular-signal-regulated 162 
kinase (ERK1/2) phosphorylation within endothelial cells [62, 63], which is likely to be a major anti-163 
proliferation pathway induced by Ang (1-7).  164 
A critical role for Ang (1-7)/Ang II has been established in endothelial dysfunction and cellular 165 
proliferation. Considering research from this laboratory is clearly providing a vasoactive role for both 166 
alamandine and Ang A [22], a trophic or anti-trophic effect on endothelial cells has not as yet been 167 
demonstrated. Therefore, future experiments similar to studies conducted for Ang (1-7) will provide the 168 
essential information necessary to compare these two heptapeptides.  169 
 170 
1.5 Ang (1-7) and Mas receptor counterbalance the effects of Ang II and AT1 receptor 171 
The Mas receptor is a G-coupled protein receptor which is expressed in brain, kidneys, testes, heart and 172 
blood vessels of both humans and mice [36, 64-67]. It is conceivable that Ang (1-7) mediated through the 173 
Mas receptor [68], may have beneficial effects in the treatment for CVD. Indeed, Ang (1-7) at 80nM has 174 
been shown to protect against hypoxia and cardiomyocyte apoptosis by preventing ROS-induced 175 
mitochondrial dysfunction in rat cell lines [69]. This suggests that Ang (1-7) may be protective in specific 176 
tissues and that it may act on mitochondria. Furthermore, a number of RAS blockers have been developed 177 
in order to reduce the effects of Ang II; such blockers (renin inhibitors, ACE inhibitors and Ang II 178 
receptor blockers) all have anti-hypertensive effects [15]. Interestingly, inhibition of Ang II via ACE1 179 
blockers increases Ang (1-7) by 5–25-fold in blood [70] and Ang (1-7) may also be involved in the anti-180 
depressant effect of ACE1 treatment in hypertensive rats [71]. This suggests that Ang (1-7) alone has an 181 
important role in blood pressure regulation via inducing vasodilation protecting endothelial function and 182 
hence, cardiovascular related diseases. Since Ang (1-7) is formed by ACE1, increasing its levels could be 183 
a viable alternative to inhibition of ACE1 in order to achieve desired plasma Ang (1-7) concentration. 184 
Likewise, alamandine has anti-hypertensive properties, enhances vasodilation and reverses endothelial 185 
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dysfunction in spontaneous hypertensive rats and homocysteine-induced endothelial dysfunction rabbits 186 
[12, 72]. Hence, as Ang (1-7) can reverse the negative effects of Ang II on endothelial dysfunction, 187 
superoxide production, as well as lowering Ang II-induced atherosclerotic lesions and plaque formation, 188 
further studies with alamandine could show similar findings, and together these heptapeptides could 189 
reduce the progression of CVD. 190 
However, controversial results on Ang (1-7)-beneficial physiological effects have been reported. In Mas 191 
knockout mice induced with unilateral ureteral obstruction (UUO) kidneys, the administration of Ang (1-192 
7) worsened renal lesions compared to untreated Mas knockout UUO mice [73], suggesting that Ang (1-193 
7) administration can be harmful in individuals with obstructed kidneys. However, one must take into 194 
account that Ang (1-7) has only been shown to exert beneficial physiological effects, such as reducing 195 
atherosclerotic plaque and inducing vasodilation, in the presence of the Mas receptor. Additionally, it has 196 
been shown that mice with UUO already develops severe renal inflammation with significant 197 
upregulation of inflammatory chemokines and cytokines such as MCP-1 and IL-6 respectively [74], 198 
suggesting that Ang (1-7) may not be a beneficial treatment at severe stages of disease, and that it may 199 
potentially exacerbate the development of disease instead. However, more studies report that chronic 200 
treatment of Ang (1-7) is able to reduce fat accumulation and inflammation in animal models of liver 201 
disease, suggesting Ang (1-7) as a strong anti-inflammatory agent [75]. Thus the model chosen plays a 202 
role in the controversial reports of any experiments related to Ang (1-7) as a treatment.  203 
Of interest, Ang (1-7) and Ang II both stimulated ERK1/2 phosphorylation and enhanced mesangial cell 204 
proliferation [76], further conflicting most reports that demonstrate the opposing effects of Ang (1-7) 205 
compared to Ang II [77, 78]. However, when co-administered to rat renal mesangial cells, Ang (1-7) 206 
inhibited the stimulatory effects induced by Ang II, which could be blocked by a Mas receptor blocker, 207 
A779, yet anti-AT1 or anti-AT2 receptor blockers had no effect [76]. Hence, although interacting with 208 
each other [79], Ang (1-7) specifically acts on the Mas receptor and Ang II specifically acts on the AT1 209 
receptor. In human umbilical vein endothelial cells (HUVEC), Ang (1-7) at 1µM had no effect on 210 
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endothelial cell apoptosis, however when HUVEC are treated with Ang II, Ang (1-7) suppresses 211 
apoptosis [80].  This indicates not only the crucial role on endothelial cell survival [62], but also that Ang 212 
(1-7) either interacts with the AT1 receptor by dislodging Ang II binding or interacts with the Mas 213 
receptor.  Similar findings were observed in aortic vascular cells of ACE2-knockout mice [81]. 214 
Furthermore, in Ang II induced endothelial dysfunction, blocking of the AT1 receptor augments the 215 
production of NO and improves vasodilation, which are crucial factors in the prevention of hypertension 216 
and atherosclerosis [82, 83]. Since, blocking of the AT1 receptor is associated with an increase of Ang (1-217 
7), the addition of Ang (1-7) may counterbalance the effects of Ang II induced endothelial dysfunction 218 
and may aid in the prevention of atherosclerosis. To this effect, ex vivo treatment of murine aortae with 219 
Ang II impairs vasodilation which is reversed by Ang (1-7) [31]; these effects are diminished following 220 
treatment with the Mas receptor antagonist, A779. These findings, suggest that endothelial dysfunction 221 
induced by Ang II (reduced NO and vasodilation), could be counterbalanced by Ang (1-7) acting through 222 
the Mas receptor. Moreover, the studies suggest that the counterbalancing effects caused by Ang (1-7) 223 
through the Mas receptor are a compensatory system that is important to balance the over-activity of Ang 224 
II through the AT1 receptor. However, the cellular mechanism underlying this theory is not yet clear, 225 
although some studies suggest a specific non-competitive inhibition of Ang (1-7) on the AT1 receptor [84, 226 
85]. Others suggest that the AT1 receptor and Mas receptor form a hetero-oligomer in order for their 227 
effects to be counterbalanced [76, 86]. Further research to establish these initial results are necessary.   228 
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Figure 2: The chemical structure of Ang II, Ang (1-7) and alamandine peptides as ligands and their corresponding receptors. Both Ang (1-7) and 230 
alamandine have similar amino acid sequence and they both function as ligands for the proto-oncogene receptors, Mas and MrgD, respectively. 231 
Upon stimulation of these receptors there is upregulation of NO from the endothelium of blood vessels. The release of NO diffuses into the 232 
vascular smooth muscle cell (VSMC) layer (as NO is a soluble gas) and induces relaxation. However, Ang II counters these effects upon 233 
stimulation of the AT1 receptor.  (NO, nitric oxide; VSMC, vascular smooth muscle cell; Red line, blocking effect; Green line, activation). 234 
 235 
 236 
 237 
1.6 Alamandine and the MrgD receptor: similarities to Ang (1-7) 238 
Alamandine, a heptapeptide, is closely related to the vasodilator Ang (1-7), with only one amino acid 239 
difference, whereby the first amino acid of Ang (1-7) is aspartate, and alanine is for alamandine. 240 
Therefore, alamandine can be synthesized from Ang (1-7) by decarboxylation of aspartate into alanine. 241 
As these peptides have similar amino acid sequence and structure (Figure 1 and 2), their effects are highly 242 
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likely to be similar. Through chromatographic approach, it was demonstrated that a peptidase exists in the 243 
medulla of sheep brain which converts Ang (1-7) into Ang (1-4) [87]. Although the peptidase was not 244 
identified, it was suggested that metalloendopeptidase may have been responsible. More recently, it was 245 
noted that the hydrolysis of alamandine may also occur via metalloendopeptidase for Ang (1-7) in kidney 246 
tissue [88].  247 
Interestingly, Chinese Hamster Ovary (CHO) cells transfected with Mas receptor and incubated with Ang 248 
(1-7) resulted in elevated NO levels and eNOS activity, which was inhibited by the Mas receptor blocker , 249 
A779. In addition, wortmannin, a specific phosphatidylinositol 3 (PI3) kinase inhibitor reduced NO levels 250 
and eNOS activity in the absence of A779 [36]. Similar effects were also noted in human aortic 251 
endothelial cells (HAEC), which constitutively express the Mas receptor [36], as well as in rat hearts [89]. 252 
In addition, Ang (1-7) through the Mas receptor activates the protein kinase B pathway (PKB) in 253 
pancreatic islet endothelial cells [62], increasing eNOS activity and NO production. However, in 254 
mesangial cells Ang (1-7) activates Mas receptor via a different protein kinase pathway, PKA, and 255 
correlates with increased cyclic AMP [90].  256 
To further understand the similar roles amongst Ang (1-7) and alamandine, we recently demonstrated that 257 
ex vivo treatment of alamandine to isolated rabbit aortas reversed homocysteine-induced endothelial 258 
dysfunction by activating the PKA pathway for vasorelaxation [72]. Although we demonstrated the 259 
presence of MrgD receptor using immunohistochemistry in another study [22], others have shown that 260 
CHO cells transfected with MrgD receptor and cultured with alamandine, high levels of NO is produced 261 
but not in normal CHO cells, suggesting that alamandine binds to MrgD receptor to induce NO 262 
production via increasing eNOS activity [12]. This specific finding establishes that alamandine binds to 263 
MrgD receptor and that the outcome is enhanced NO production through eNOS, the enzyme that produces 264 
NO within endothelial cells. Whilst these studies were conducted in non-diseased cells [12], we 265 
previously demonstrated that alamandine was not able to prevent endothelial dysfunction in atherogenic-266 
diet fed rabbits, however alamandine is likely to exert more acetylcholine-mediated vasodilation in 267 
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thoracic and carotid artery compared to acetylcholine-exerted vasodilation alone in these atherogenic 268 
vessels [22]. These studies clearly suggest that the role of alamandine may exert beneficial vasodilatory 269 
effects on the initial steps of atherosclerosis and may not play a role in advanced stages of atherosclerosis. 270 
Possibly, the function and expressions of MrgD receptor on the endothelial cell layer may not be 271 
sufficient or efficient when the vessel is completely dysfunctional and, therefore, alamandine has no 272 
beneficial effects in such conditions. Hence, early intervention needs to be considered when treating 273 
atherosclerosis with alamandine. 274 
Moreover, in organ bath experiments, individual incubations of alamandine and Ang (1-7) were not able 275 
to reduce Ang II mediated vasoconstriction [22]. Conversely, Ang (1-7) has been shown to reverse Ang 276 
II-mediated endothelial dysfunction in mouse aorta [31]. Although the results are conflicting, differing 277 
experimental conditions exist. In our study [22], the vessels were incubated with the RAS peptides and 278 
then a dose-response curve to Ang II was constructed, whereas in [31],  the vessels were initially 279 
incubated with Ang II in organ cultures for 24 hours and then Ang (1-7) was incubated, where 30 minutes 280 
after this point a dose-response curve to acetylcholine was constructed [31]. These differences suggest 281 
that further studies are required to elucidate the roles of alamandine and Ang (1-7) during diseased states 282 
such as atherosclerosis.    283 
 284 
1.7 Conclusion 285 
Studies from our and other laboratories show that Ang (1-7) and alamandine are able to promote 286 
beneficial effects on the cardiovascular system, such as, counterbalancing Ang II-associated endothelial 287 
dysfunction and therefore, may reduce the development of Ang II associated atherosclerosis.    288 
 289 
Table 1: A summary of the novel renin angiotensin system (RAS) components and their function and 290 
mechanisms on endothelial cells 291 
RAS peptides Reference Induce or Other cardiovascular Mechanism 
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and receptors prevent 
endothelial 
dysfunction? 
harmful or protective 
effects? 
Ang II [46-48] Induce 
Involved in 
hypertension, smooth 
muscle cell 
proliferation 
Through NADPH oxidase, 
reduction in NO 
Ang A [14, 22] Remains unknown  Vasoconstrictor  Possibly through the AT1 receptor 
Ang 1-7 [22, 31]  Prevent Anti-proliferative effects, vasodilation 
Counterbalance Ang II 
actions by increasing 
eNOS activity, and thus 
NO production 
Alamandine 
 
[12, 22, 
72] 
 
Prevent Anti-hypertensive effects, vasodilation 
May potentially 
counterbalance Ang-II 
actions 
AT1 receptor 
 
[82, 83] 
 
Upon agonistic 
stimulation; 
induce 
Upon agonistic 
stimulation, 
vasoconstriction 
Superoxide production, 
increase in NADPH 
oxidase expression 
Mas receptor [36] Prevent 
Upon agonistic 
stimulation, 
vasodilation 
Increase in eNOS activity, 
NO production, and 
reduction in superoxide 
production 
MrgD 
receptor 
[12, 72] 
 Prevent 
Upon agonistic 
stimulation, 
vasodilation 
Increase in eNOS activity, 
NO production via PKA 
pathway 
Ang, Angiotensin; AT1, Angiotensin II type I receptor; eNOS, endothelial nitric oxide synthase; NADPH, 292 
nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; PKA, protein kinase A.  293 
 294 
 295 
 296 
 297 
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